Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0106 USD | -3.64% | -33.75% | -51.82% |
Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Financials (USD)
Sales 2021 | 1.08 | Sales 2022 | 1.27 | Capitalization | 1.76M |
---|---|---|---|---|---|
Net income 2021 | -19M | Net income 2022 | -58M | EV / Sales 2021 | 17,166,252 x |
Net cash position 2021 | 6.35 | Net Debt 2022 | 2.68 | EV / Sales 2022 | 1,390,484 x |
P/E ratio 2021 |
-0.76
x | P/E ratio 2022 |
-0.02
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.98% |
Latest transcript on Baudax Bio, Inc.
1 day | -3.64% | ||
1 week | -33.75% | ||
Current month | -18.46% | ||
1 month | -24.29% | ||
3 months | -61.31% | ||
6 months | -95.14% | ||
Current year | -51.82% |
Managers | Title | Age | Since |
---|---|---|---|
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Natalie McAndrew
DFI | Director of Finance/CFO | 50 | 23-10-08 |
Diane Myers
PRN | Corporate Officer/Principal | 60 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 19-11-20 | |
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Wayne Weisman
CHM | Chairman | 68 | 19-11-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.0106 | -3.64% | 16,443 |
24-04-18 | 0.011 | +3.77% | 76,511 |
24-04-17 | 0.0106 | -7.83% | 109,561 |
24-04-16 | 0.0115 | -28.12% | 164,168 |
24-04-15 | 0.016 | 0.00% | 12,961 |
Delayed Quote OTC Markets, April 19, 2024 at 03:02 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-51.82% | 577K | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- BXRXQ Stock